INT17326

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 11.72
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plg) extracellular space (Plg) extracellular region (Plg)
Anatomy Link Frequency
bowel 2
plasma 1
body 1
T cells 1
Plg (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 73 99.76 Very High Very High Very High
Infliximab 20 99.34 Very High Very High Very High
Potency 7 99.20 Very High Very High Very High
Crohn's disease 40 99.12 Very High Very High Very High
spondylitis 5 96.72 Very High Very High Very High
methotrexate 15 96.56 Very High Very High Very High
Arthritis 23 96.48 Very High Very High Very High
rheumatoid arthritis 11 96.46 Very High Very High Very High
Pain 31 96.44 Very High Very High Very High
spinal inflammation 1 92.92 High High
Disease Link Frequency Relevance Heat
Pyoderma Gangrenosum 350 100.00 Very High Very High Very High
Inflammatory Bowel Disease 55 99.76 Very High Very High Very High
Myelodysplastic Syndromes 5 99.52 Very High Very High Very High
Erythema 5 99.32 Very High Very High Very High
Disease 228 99.20 Very High Very High Very High
Lymphatic System Cancer 10 98.92 Very High Very High Very High
Necrosis 39 98.80 Very High Very High Very High
Leukemia 10 98.72 Very High Very High Very High
Cancer 146 98.62 Very High Very High Very High
Paraproteinemias 5 98.50 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The plasminogen system is negatively controlled by the action of soluble protein inhibitors that selectively bind plasminogen or plasmin.
plasminogen Binding (bind) of
1) Confidence 0.43 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.18 Pain Relevance 0.04
The plasminogen system is negatively controlled by the action of soluble protein inhibitors that selectively bind plasminogen or plasmin.
plasmin Binding (bind) of
2) Confidence 0.37 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.18 Pain Relevance 0.04
The low eudismic ratios of the alpha-methyl derivatives and the observation that the side chain may be extended by three methylene groups without significant loss of PG inhibitory potency suggests that this class of inhibitors bound less strongly and less selectively to the active site of PG synthetase than do the arylacetic acids.
PG synthetase Binding (bound) of associated with potency
3) Confidence 0.36 Published 1991 Journal J. Med. Chem. Section Abstract Doc Link 1900533 Disease Relevance 0 Pain Relevance 0.30
To further characterize the nature of the autopathogenic effector T cells operating in these mice and to determine the region(s) of the PG molecule recognized by these T cells, we generated PG-specific T cell hybridomas from arthritic mice.
PG Binding (recognized) of in T cells associated with arthritis
4) Confidence 0.20 Published 1995 Journal J. Immunol. Section Abstract Doc Link 7544381 Disease Relevance 0.58 Pain Relevance 0.20
In addition, plasmin generation is dependent on the binding of plasminogen to the plasma membrane [41].
plasminogen Binding ( on the) of in plasma
5) Confidence 0.17 Published 2008 Journal Neurochem Res Section Body Doc Link PMC2758381 Disease Relevance 0 Pain Relevance 0
In particular, Stachybotrys microspora triprenyl phenol-7 (SMTP-7; Orniplabin, MW 869.1, Fig. 1) is five to ten times more potent than staplabin in enhancing plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation (Hu et al. 2000).
plasminogen Binding (binding) of
6) Confidence 0.10 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.62 Pain Relevance 0.04
They found that differential production of u-PA corresponded with the ability of the more aggressive lines to bind and activate plasminogen; thus providing direct support that u-PA secretion and the levels of u-PA- u-PAR complexes characterize the invasive phenotype of these cells [118].
plasminogen Binding (bind) of
7) Confidence 0.03 Published 2004 Journal Reprod Biol Endocrinol Section Body Doc Link PMC320496 Disease Relevance 0.39 Pain Relevance 0
However, local fibrinolysis in vivo mediated by t-PA may be independent of complex formation between plasminogen activator inhibitors and t-PA in the fluid phase.
plasminogen Binding (formation) of
8) Confidence 0.03 Published 1993 Journal Dan Med Bull Section Abstract Doc Link 8222763 Disease Relevance 0.07 Pain Relevance 0
TSP-1, tumstatin, angiostatin, and 16K hPRL are strongly recommended.
angiostatin Binding (recommended) of
9) Confidence 0.03 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 1.03 Pain Relevance 0.03
In many cases, PG is associated with inflammatory bowel disease, rheumatic disorder or neoplasia [1-3].
PG Binding (associated) of in bowel associated with inflammation, cancer and pyoderma gangrenosum
10) Confidence 0.01 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1857704 Disease Relevance 1.47 Pain Relevance 0.19
Tumour necrosis alpha inhibitor infliximab was reported to be effective in PG associated with inflammatory bowel disease at a dosage of 5 mg/kg body weight.
PG Binding (associated) of in body associated with necrosis, body weight, inflammation, infliximab, cancer and pyoderma gangrenosum
11) Confidence 0.01 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1857704 Disease Relevance 1.49 Pain Relevance 0.39
In many cases PG is associated with an underlying disease, most commonly inflammatory bowel disease, rheumatic or haematological disease and malignancy.
PG Binding (associated) of in bowel associated with malignant neoplastic disease, hematological disease, inflammation, disease and pyoderma gangrenosum
12) Confidence 0.01 Published 2007 Journal Orphanet J Rare Dis Section Abstract Doc Link PMC1857704 Disease Relevance 1.38 Pain Relevance 0.14
Hepatitis C, seronegative rheumatoid arthritis, spondylitis, and a broad spectrum of lymphoproliferative disorders including monoclonal gammopathies, leukaemia, lymphoma, and myelodysplastic syndrome have been described in association with PG [2,4,25,26].
PG Binding (association) of associated with leukemia, spondylitis, lymphatic system cancer, paraproteinemias, rheumatoid arthritis, myelodysplastic syndromes, lymphoproliferative disease, hepatitis c virus infection and pyoderma gangrenosum
13) Confidence 0.01 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1857704 Disease Relevance 3.37 Pain Relevance 0.40
In cases of Crohn's associated PG may achieve long term remissions with this regimen lasting for up to 30 months [49].
PG Binding (associated) of associated with pyoderma gangrenosum
14) Confidence 0.01 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1857704 Disease Relevance 0.95 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox